Approved Ligands

Canagliflozin inhibits Na+- dependent 14C-AMG uptake in a concentration-dependent fashion. It is a novel C-glucoside with thiophene ring.

Canagliflozin inhibits Na+- dependent 14C-AMG uptake in a concentration-dependent fashion. It is a novel C-glucoside with thiophene ring.

Candesartan is an angiotensin II receptor antagonist with IC50 of 0.26 nM.A selective angiotensin II receptor antagonist.Application：CAN may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical

Candesartan is an angiotensin II receptor antagonist with IC50 of 0.26 nM.A selective angiotensin II receptor antagonist.Application：CAN may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical

Candesartan is an angiotensin II receptor antagonist with IC50 of 0.26 nM.A selective angiotensin II receptor antagonist.Application：CAN may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical

Candesartan is an angiotensin II receptor antagonist with IC50 of 0.26 nM.A selective angiotensin II receptor antagonist.Application：CAN may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical

Capmatinib (INCB28060) is a novel, ATP-competitive inhibitor of c-MET with IC50 of 0.13 nM in a cell-free assay, inactive against RONβ, as well as EGFR and HER-3.A novel inhibitor of Met (IC50 = 0.13 nM).

Capmatinib (INCB28060) is a novel, ATP-competitive inhibitor of c-MET with IC50 of 0.13 nM in a cell-free assay, inactive against RONβ, as well as EGFR and HER-3.A novel inhibitor of Met (IC50 = 0.13 nM).

Capmatinib (INCB28060) is a novel, ATP-competitive inhibitor of c-MET with IC50 of 0.13 nM in a cell-free assay, inactive against RONβ, as well as EGFR and HER-3.A novel inhibitor of Met (IC50 = 0.13 nM).

Capmatinib (INCB28060) is a novel, ATP-competitive inhibitor of c-MET with IC50 of 0.13 nM in a cell-free assay, inactive against RONβ, as well as EGFR and HER-3.A novel inhibitor of Met (IC50 = 0.13 nM).

Capmatinib (INCB28060) is a novel, ATP-competitive inhibitor of c-MET with IC50 of 0.13 nM in a cell-free assay, inactive against RONβ, as well as EGFR and HER-3.A novel inhibitor of Met (IC50 = 0.13 nM).

Capmatinib (INCB28060) is a novel, ATP-competitive inhibitor of c-MET with IC50 of 0.13 nM in a cell-free assay, inactive against RONβ, as well as EGFR and HER-3.A novel inhibitor of Met (IC50 = 0.13 nM).